Impact of COVID-19 vaccination coverage on global disability burden of Guillain-Barré syndrome.

IF 6.5 1区医学 Q1 IMMUNOLOGY

NPJ Vaccines Pub Date : 2025-08-02 DOI:10.1038/s41541-025-01239-1

Xīn Gào, Chen Zhao, Junting Yang, Ziming Yang, Jingnan Feng, Siyan Zhan, Dongsheng Fan, Zhike Liu

{"title":"Impact of COVID-19 vaccination coverage on global disability burden of Guillain-Barré syndrome.","authors":"Xīn Gào, Chen Zhao, Junting Yang, Ziming Yang, Jingnan Feng, Siyan Zhan, Dongsheng Fan, Zhike Liu","doi":"10.1038/s41541-025-01239-1","DOIUrl":null,"url":null,"abstract":"<p><p>The global burden of Guillain-Barré syndrome (GBS), an immune-mediated neuropathy, remains poorly characterized during the COVID-19 pandemic. We analyzed age-standardized years lived with disability (YLD) for GBS from 1990 to 2021 using GBD 2021 data and COVID-19 vaccination coverage from Our World in Data, focusing on 2020-2021. During the pandemic, GBS YLD rates rose dramatically, with greater increases seen in low-SDI regions, females and individuals aged 15-29 years. Higher vaccination coverage was inversely associated with GBS disability burden, exhibiting a non-linear protective effect at moderate to high coverage levels. Causal mediation analysis indicated that 44.6% of this association was mediated by reductions in COVID-19 incidence, highlighting both direct and indirect neuroprotective benefits of vaccination programs. These results underscore the importance of sustaining and expanding the vaccine rollout to mitigate the secondary neurological burden associated with emerging infections.</p>","PeriodicalId":19335,"journal":{"name":"NPJ Vaccines","volume":"10 1","pages":"182"},"PeriodicalIF":6.5000,"publicationDate":"2025-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12318086/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"NPJ Vaccines","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41541-025-01239-1","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

The global burden of Guillain-Barré syndrome (GBS), an immune-mediated neuropathy, remains poorly characterized during the COVID-19 pandemic. We analyzed age-standardized years lived with disability (YLD) for GBS from 1990 to 2021 using GBD 2021 data and COVID-19 vaccination coverage from Our World in Data, focusing on 2020-2021. During the pandemic, GBS YLD rates rose dramatically, with greater increases seen in low-SDI regions, females and individuals aged 15-29 years. Higher vaccination coverage was inversely associated with GBS disability burden, exhibiting a non-linear protective effect at moderate to high coverage levels. Causal mediation analysis indicated that 44.6% of this association was mediated by reductions in COVID-19 incidence, highlighting both direct and indirect neuroprotective benefits of vaccination programs. These results underscore the importance of sustaining and expanding the vaccine rollout to mitigate the secondary neurological burden associated with emerging infections.

查看原文本刊更多论文

COVID-19疫苗接种覆盖率对格林-巴- 综合征全球残疾负担的影响

在2019冠状病毒病大流行期间，格林-巴- 综合征（GBS）这一免疫介导的神经病变的全球负担仍然缺乏特征。我们使用GBD 2021数据和来自Our World in data的COVID-19疫苗接种覆盖率分析了1990年至2021年GBS的年龄标准化残疾生活年（YLD），重点是2020-2021年。在大流行期间，GBS - YLD发病率急剧上升，在低sdi地区、女性和15-29岁的个人中增幅更大。较高的疫苗接种覆盖率与GBS残疾负担呈负相关，在中等至高覆盖率水平上表现出非线性的保护作用。因果中介分析表明，44.6%的关联是由COVID-19发病率降低介导的，这突出了疫苗接种计划的直接和间接神经保护益处。这些结果强调了维持和扩大疫苗推广以减轻与新发感染相关的继发性神经负担的重要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

NPJ Vaccines Immunology and Microbiology-Immunology

CiteScore

11.90

自引率

4.30%

发文量

146

审稿时长

11 weeks

期刊介绍： Online-only and open access, npj Vaccines is dedicated to highlighting the most important scientific advances in vaccine research and development.